Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
It functions as a dual GLP-1 and GIP receptor agonist , offering: Enhanced insulin secretion Delayed gastric emptying Appetite suppression Improved glycemic control Tirzepatide demonstrated impressive clinical outcomes in the SURMOUNT and SURPASS trials, with average weight loss of 15-22.5% and substantial A1C reductions
Furthermore, key features include: 99% purity, confirmed by reverse-phase HPLC with controlled impurity profiles 10 mg vial format Lyophilized powder suitable for controlled laboratory reconstitution and measured research use Selective multi-receptor activity Binds melanocortin receptors (MC1R, MC3R, MC4R, MC5R) for comprehensive receptor pharmacology investigations Engineered stability Nle and D-Phe substitutions at positions 4 and 7 enhance enzymatic resistance compared to native -MSH cAMP-dependent signaling Investigated for activation of second-messenger cascades and downstream transcriptional responses Stable freeze-dried formulation Lyophilized for long-term stability at 18 C with minimal degradation For laboratory research use only How is MT-1 synthesized
Those are class-relevant issues across GLP-1 and incretin-based drugs
Oral semaglutide Oral semaglutide drops and sublingual semaglutide have become available through some compounding pharmacies
Nocito MC, Hantel C, Lerario AM, Mastrorocco F, De Martino L, Musicco C, et al
Dysfunction in these pathways can trigger neurodegeneration and motor dysfunction
